Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: DNLI denalitherapeutics.com
Denali Therapeutics Inc. is a biotechnology company focused on developing biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle (TV) platform. The company's first FDA-approved product, AVLAYAH (tividenofusp alfa-eknm), treats neurologic manifestations of Hunter syndrome (MPS II) and is the first biologic approved to leverage transferrin receptor to cross the BBB. Denali's pipeline spans lysosomal storage disorders and neurodegenerative diseases including Sanfilippo syndrome, frontotemporal dementia, Alzheimer's disease, Pompe disease, and Parkinson's disease. The TV platform encompasses multiple modalities — Enzyme TransportVehicle (ETV), Protein TransportVehicle (PTV), and Oligonucleotide TransportVehicle (OTV) — enabling delivery of enzymes, proteins, and oligonucleotides across the BBB. The company collaborates with Biogen on a LRRK2 inhibitor program for Parkinson's disease and has a synthetic royalty funding agreement with Royalty Pharma. Denali trades on the Nasdaq under the ticker DNLI. Updated
The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names…
Wednesday's additional analyst upgrades and downgrades included CrowdStrike, Ecolab, KKR, Microsoft, Tilray Brands and Twilio.
Monday's top analyst upgrades and downgrades included Broadcom, Costco Wholesale, DraftKings, Exxon Mobil, Foot Locker, Marvell Technology, Nvidia, Payoneer Global, Philip Morris International, Pure Storage, Rivian Automotive, SoFi Technologies, Splunk and Tilray…
Tuesday's top analyst upgrades and downgrades included AT&T, Comcast, First Solar, Fortinet, Jefferies Financial, Next Era Energy Partners, T-Mobile and Walt Disney.
Wednesday’s top analyst upgrades and downgrades included Apple, AMC Entertainment, Facebook, First Solar, Kansas City Southern, Roku and SolarEdge.
Monday's top analyst upgrades and downgrades included Albermarle, Apple, Consolidated Edison, Etsy, GoHealth, Hecla Mining, NortonLifeLock, Pinterest, Switch and T-Mobile.
Denali Therapeutics Inc. is a biotechnology company focused on developing biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle (TV) platform.
The Wall Street consensus 12-month price target for DNLI is $35.50.
